The post AAVE Price: Governance Clash Triggers 18% Weekly Drop as Stani Kulechov Buys the Dip appeared on BitcoinEthereumNews.com. TLDR Aave Labs submitted a brandThe post AAVE Price: Governance Clash Triggers 18% Weekly Drop as Stani Kulechov Buys the Dip appeared on BitcoinEthereumNews.com. TLDR Aave Labs submitted a brand

AAVE Price: Governance Clash Triggers 18% Weekly Drop as Stani Kulechov Buys the Dip

TLDR

  • Aave Labs submitted a brand control proposal without the original author’s consent, escalating DAO governance tensions.
  • The AAVE price has dropped 18% in one week, including 4.75% in one day.
  • Ernesto Boado disavowed the proposal submission, criticizing the rushed timeline and lack of prior notice.
  • Aave Labs replaced ParaSwap with CoW Swap, redirecting $200K/week in fees from the DAO to company-controlled addresses.
  • Founder Stani Kulechov purchased 84,033 AAVE worth $12.6M in a week, currently facing an unrealized loss of $2.2M.

In our recent report, Blockonomi revealed the ongoing misunderstanding between Aave Labs and the DAO over protocol ownership and governance. The tension escalated after Aave Labs submitted a brand control proposal to Snapshot without the original author’s consent.

Boado Disavows Vote Submission by Aave Labs

A recap of what really happened, as per our report, reveals that Ernesto Boado, co-founder of BGD Labs, publicly rejected the vote, stating, “This is not, in ethos, my proposal.”  He confirmed that Aave Labs submitted the draft without notice and objected to the rushed timeline during the holidays.

The proposal sought to transfer ownership of key assets like aave.com, GitHub, and social accounts to a DAO-controlled entity.  Boado clarified that he would not have approved the current version or timing of the submission.  Stani Kulechov, Aave’s founder, responded by defending the vote’s legality under the DAO’s governance process.

Earlier, Aave Labs replaced ParaSwap with CoW Swap, shifting $200K/week in fees from the DAO to itself. Delegates said the change lacked approval and diverted revenue generated through the DAO’s liquidity.  Aave Labs argued the frontend remains separate and voluntary contributions were never guaranteed.

AAVE Price Drops to $152

According to the latest CoinMarketCap data, AAVE price is currently trading at $152.49, representing a 4.75% decrease over the last 24 hours. The AAVE price has shown a consistent downward trend throughout the day, with a brief recovery failing to hold above $154. The chart indicates a peak near $161, followed by a steady decline.

Source: CoinMarketCap

The market cap has also dropped 4.75%, now sitting at $2.33 billion. Trading volume, however, rose 34.59% over the same period, reaching $708.52 million. The volume-to-market capitalization ratio is currently 30.44%, indicating increased short-term activity.

AAVE’s fully diluted valuation stands at $2.43 billion, while total value locked (TVL) is reported at $33.74 billion. The market cap-to-TVL ratio is 0.06928, indicating a disparity between token value and protocol usage.

Stani Kulechov Accumulates 84K AAVE, Faces $2.2M Unrealized Loss

Despite the ongoing saga and AAVE price dip, a post on X by Lookonchain reveals that Stani Kulechov executed multiple AAVE-related transactions through Gnosis Safe and CoW Protocol. He purchased a total of 32,660 AAVE, valued at approximately $5.15 million, at an average price of $158. The transactions include inflows and outflows involving WETH and AAVE, routed via settlement contracts.

He received 935.234 WETH from CoW Protocol and transferred 48.793 WETH back, equaling about $147.7K. Other transactions show repeated movement of WETH and Aave Labs tokens between wallets linked to him and the protocol. One entry indicates 569.329 AAVE moved from CoW Protocol to Stani Kulechov’s Gnosis wallet.

Over the past week, Stani accumulated a total of 84,033 AAVE, valued at $12.6 million, at an average cost of $176. Based on the current AAVE market price, his position shows an unrealized loss of approximately $2.2 million.

The post AAVE Price: Governance Clash Triggers 18% Weekly Drop as Stani Kulechov Buys the Dip appeared first on Blockonomi.

Source: https://blockonomi.com/aave-price-governance-clash-triggers-18-weekly-drop-as-stani-kulechov-buys-the-dip/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26